Today, the Court of Appeals for the Federal Circuit affirmed in part and reversed in part the original decision in Association for Molecular Pathology, et al. v. United States Patent and Trademark Office, et al. Specifically, it stated that Myriad Genetics’ composition claims to isolated DNA were valid. What’s your thoughts on this latest decision in the long-standing debate over patenting genes.

Poll Question:
Do you agree with the Court’s most recent decision validating Myriad’s composition claims to isolated DNA?

Yes
13

No
32

Undecided
6

Previous articleCourt of Appeals Rules that Myriad’s Patents on BRCA Genes Are Valid
Next articleEfforts to Standardize Molecular Imaging Blossoms as Industry and Agencies Unite